TMDX

Transmedics Group Inc

$28.82

chg

-0.08 (-0.28%)

quotes and stock data may be delayed 15 minutes

52 wk low

11.51

52 wk hi

49.5

Cash

$118.1M

Burn Rate (Qtr)

$6.5M

Mkt Cap

$796.1m

Avg Volume

450,154

*cash/burn updated:

Q1 '21

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We have found any drug for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Loading Catalysts...

search in progress

Pipeline powered by

TMDX

BPIQ_Logo_RGB-01.jpg

Company Profile

TransMedics was founded to address the growing need for healthier organs for transplantation. We are focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs.

The Organ Care System (OCS™) platform is a revolutionary technology for preserving organs used in the treatment of end-stage heart, lung, and liver failure.

The OCS is the first and only multi-organ platform to leverage proprietary core technologies across multiple organs.

Recent Posts

See what the community is saying - click to see full post.

TMDX - TransMedics Reports Third Quarter 2020 Financial Results